Keyword: Rubraca

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.

Thursday was a busy day for Europe’s regulators—and their whirl of activity will send several drugmakers into the weekend happy.

Tesaro is issuing a safety warning for the injected version of Varubi after patients experienced anaphylaxis and anaphylactic shock.

AstraZeneca and Merck's first-in-class ovarian cancer drug Lynparza just won a coveted approval to treat BRCA-mutated breast cancer.

Clovis is one step away from a new use for its ovarian cancer drug Rubraca—and with FDA priority review, it could take that step early next year.

If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula has the lead in ovarian cancer. But that could change.

Ovarian cancer patients who respond to chemo have new treatment options, but a cost watchdog isn’t convinced they're worth the price.

Tesaro is in strong position to win another regulatory victory for its drug Zejula, which could boost its standing in the market for PARP inhibitors to treat ovarian cancer.

Clovis may be the middle child among next-gen ovarian cancer meds, but it’s hoping new data will open the therapy to a wave of new patients.

Sorry, Tesaro. AZ's Lynparza won a broader-than-expected approval in ovarian cancer, putting it on even footing with Tesaro’s recent launch, Zejula.